Extended-release oral systems will revolutionize current clinical-care models and maximize effective treatment for a wide range of diseases in a variety of clinical settings.
Giovanni Traverso & Robert Langer
Despite decades of scientific efforts to develop extended drug release technologies, the current oral formulations on the market only extend therapeutic serum delivery to 12-24 hours. The Lyndra team -- comprised of MIT and Harvard scientists and physician scientists -- has for the first time developed a technology that extends oral drug delivery beyond one week.
Lyndra envisions a world in which patients realize the full potential benefit of their medical care and where the overall burden on the healthcare system is reduced.
C. Everett Koop, the former U.S. Surgeon General, famously said, “Drugs don’t work in people who don’t take them.” Although this is self-evident, it was stimulated by what has been called, “America’s other drug problem” (National Council on Patient Information and Education, 2013). An alarming percentage of people do not, in fact, take their medications as directed.
Kendall Square — the Cambridge, Mass., hub of biotech, pharma, and MIT — is a hard place to pick just three people to keep an eye on. So much goes on there that affects the greater life science industry: Deals are struck, drugs are discovered, companies are formed — and all that happens within walking distance.